Insider Sale: Collegium Pharmaceutical, Inc. (NASDAQ: COLL) Executive Vice President Sells 38,589 Shares

Collegium Pharmaceutical, Inc. (NASDAQ: COLL – Get a rating) Executive Vice President Shirley R. Kuhlmann sold 38,589 shares in a trade that took place on Thursday, September 15. The shares were sold at an average price of $18.07, for a total transaction of $697,303.23. Following the sale, the executive vice president now directly owns 109,495 shares of the company, valued at $1,978,574.65. The sale was disclosed in an SEC filing, which is available via this link.

Price performance of Collegium Pharmaceutical

Shares of COLL traded down $0.80 on Friday, hitting $17.29. The company’s stock had a trading volume of 485,827 shares, compared to an average trading volume of 329,257. The stock’s fifty-day simple moving average is $17.83 and its 200-day simple moving average is 17. $55. Collegium Pharmaceutical, Inc. has a 1-year low of $14.04 and a 1-year high of $22.89. The company has a current ratio of 0.99, a quick ratio of 0.80 and a debt ratio of 3.16.

Collegium Pharmaceutical (NASDAQ: COLL- Get a rating) last reported results on Thursday, August 4. The specialty pharmaceutical company reported ($0.04) earnings per share for the quarter, missing analyst consensus estimates of $1.15 per ($1.19). The company posted revenue of $123.55 million in the quarter, compared to $122.63 million expected by analysts. Collegium Pharmaceutical recorded a negative net margin of 11.24% and a negative return on equity of 2.12%. Equity analysts expect Collegium Pharmaceutical, Inc. to post EPS of 4.21 for the current year.

Institutional entries and exits

Institutional investors and hedge funds have recently been buying and selling shares of the company. Summit Global Investments increased its position in shares of Collegium Pharmaceutical by 103.7% during the second quarter. Summit Global Investments now owns 110,606 shares of the specialty pharmaceutical company worth $1,960,000 after buying an additional 56,306 shares in the last quarter. Jane Street Group LLC purchased a new stake in shares of Collegium Pharmaceutical during the second quarter at a value of $443,000. Tamarack Advisers LP purchased a new stake in shares of Collegium Pharmaceutical during the second quarter at a value of $1,772,000. Thrivent Financial for Lutherans increased its position in shares of Collegium Pharmaceutical by 18.6% during the second quarter. Thrivent Financial for Lutherans now owns 33,377 shares of the specialty pharmaceutical company worth $591,000 after buying an additional 5,235 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD increased its position in shares of Collegium Pharmaceutical by 5.9% during the second quarter. Price T Rowe Associates Inc. MD now owns 25,580 shares of the specialty pharmaceutical company worth $453,000 after buying 1,425 additional shares in the last quarter.

Wall Street analysts predict growth

A number of equity research analysts have published reports on COLL shares. StockNews.com downgraded shares of Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a Thursday, May 19, report. HC Wainwright downgraded shares of Collegium Pharmaceutical to a “neutral” rating in a Monday, August 15 report. Two investment analysts gave the stock a hold rating and three gave the stock a buy rating. According to data from MarketBeat.com, the company currently has an average “Moderate Buy” rating and an average target price of $33.25.

About Collegium Pharmaceutical

(Get a rating)

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and markets drugs for pain management. Its portfolio includes Xtampza ER, an oral, extended-release, abuse-deterrent oxycodone formulation; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid therapy.

Featured Articles

This instant news alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]

Before you consider Collegium Pharmaceutical, you’ll want to hear this.

MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and Collegium Pharmaceutical didn’t make the list.

While Collegium Pharmaceutical currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the five actions here